NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

具有胚胎轉移的軟組織腫瘤(STS):市場考慮因素,流行病學,市場預測(-2030)

Soft Tissue Sarcoma (STS) with lung metastases - Market Insights, Epidemiology, and Market Forecast-2030

出版商 DelveInsight Business Research LLP 商品編碼 980949
出版日期 按訂單生產 內容資訊 英文 108 Pages
商品交期: 2-10個工作天內
價格
具有胚胎轉移的軟組織腫瘤(STS):市場考慮因素,流行病學,市場預測(-2030) Soft Tissue Sarcoma (STS) with lung metastases - Market Insights, Epidemiology, and Market Forecast-2030
出版日期: 按訂單生產內容資訊: 英文 108 Pages
簡介

2017年,七個主要市場中有胚胎轉移的軟組織腫瘤(STS)的市場規模為1.7745億美元。在五個歐洲國家中,德國的最大市場規模為2371萬美元。意大利是2017年最小的市場,市場規模為1,140萬美元。

DelveInsight估計,2017年七個主要市場中有胚胎轉移的軟組織腫瘤(STS)數量為7,871。在美國,有2,506例,並且例數很高。

本報告調查了美國,五個歐洲國家(德國,西班牙,意大利,法國和英國)以及日本的七個主要市場中發生胚胎轉移的軟組織腫瘤(STS)市場。療法,新藥,每種療法的市場份額,市場規模預測等,並分析影響市場增長的因素和障礙,未滿足的需求,機會和潛力。

目錄

第1章重要見識

第2章伴有胚胎轉移的軟組織腫瘤(STS)執行摘要

第3章具有胚胎轉移的軟組織腫瘤(STS)市場概述

  • 市場份額(%)分佈
  • 市場份額(%)分佈預測

第4章具有胚胎轉移(STS)的軟組織腫瘤:疾病背景和概述

  • 簡介
  • 肺轉移的一般症狀
  • 預後因素
    • 組織學
    • 無病期(DFI)
    • 完全切除
    • 對化學療法的反應
  • 登台系統
  • 診斷為肺轉移的軟組織腫瘤(STS)

第5章病例報告

  • 跨學科治療胸壁巨大軟組織肉瘤:病例報告
  • 氣胸是軟組織肉瘤經艾瑞布林治療後發生肺轉移的不良事件
  • 初治後20年原發性肺泡軟組織肉瘤的肺轉移

第6章流行病學和患者人群

  • 主要調查結果
  • 流行病學調查方法
  • 7個主要市場的軟組織腫瘤總數(STS)
  • 7個主要市場中發生肺轉移的軟組織腫瘤(STS)總數

第7章美國流行病學

  • 先決條件和理由
  • 美國軟組織肉瘤(STS)病例總數
  • 在美國有肺轉移的軟組織腫瘤(STS)總數
  • 在美國有肺轉移的軟組織腫瘤(STS)數量:性別
  • 在美國有肺轉移的軟組織腫瘤(STS)數量:按亞型

第8章,5個歐洲國家的流行病學

  • 先決條件和理由
  • 德國流行病學
  • 法國流行病學
  • 意大利流行病學
  • 西班牙流行病學
  • 英國流行病學

第9章日本流行病學

  • 先決條件和理由
    • 患有軟組織肉瘤(STS)的患者總數
    • 伴有肺轉移的軟組織腫瘤(STS)總數
    • 伴有肺轉移的軟組織腫瘤(STS)數量:性別
    • 有肺轉移的軟組織腫瘤(STS)數量:按亞型

第10章當前的治療方法和醫學實踐

  • 手術技術與管理
  • 輔助治療
  • 處理算法

第11章未滿足的需求

第12章新藥

  • Annamycin: Moleculin
    • 產品說明
    • 其他發展活動
    • 臨床發展
    • 產品簡介

第13章患者旅程

第14章有肺轉移的STS:7個主要市場的分析

  • 主要調查結果
  • 市場調查方法
  • 市場規模
  • 市場規模:按處理方法

第15章對7個主要市場的展望

第16章美國

  • 美國市場規模
    • 總市場規模
    • 市場規模:按治療方法

第17章歐洲五國市場

  • 德國市場規模
  • 法國市場規模
  • 意大利市場規模
  • 西班牙市場規模
  • 英國市場規模

第18章日本

  • 日本市場規模

第19章市場驅動因素

第20章市場壁壘

第21章SWOT分析

第22章許可設施

第23章附錄

  • 參考
  • 報告調查方法

第24章Delve Insight服務內容

第25章免責聲明

第26章關於Delve Insight

目錄
Product Code: DIMI1266

DelveInsight's 'Soft Tissue Sarcoma (STS) with lung metastases-Market Insights, Epidemiology, and Market Forecast-2030' report deliver an in-depth understanding of the STS with lung metastases, historical and forecasted epidemiology as well as the STS with lung metastases market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The STS with lung metastases market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM STS with lung metastases market size from 2017 to 2030. The Report also covers current STS with lung metastases treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

STS with lung metastases Disease Understanding and Treatment Algorithm

STS with lung metastases Overview

Soft tissue sarcoma is a broad term for cancers that start in soft tissues (muscle, tendons, fat, lymph and blood vessels, and nerves). These cancers can develop anywhere in the body but are found mostly in the arms, legs, chest, and abdomen. For patients with STS, the lungs are the most common site of metastatic disease. Although pulmonary metastases most commonly arise from primary tumors in the extremities, they may arise from almost any primary site or histology. It was also analyzed that, approximately 20-25% of all STS patients will develop pulmonary metastases (40-60% for high-grade tumors), which will become clinically evident usually in the first 2 years following diagnosis. For extremity STS, radiotherapy, in addition to surgical removal of the tumor has been shown to reduce the risk of local recurrence, but it has no impact on survival. However, guidelines for the performance of pulmonary metastasectomy for STS do not exist, and decisions to operate are often made on an individual basis. Up to half of the STS, patients develop one or more lung metastases. Without effective systemic therapies, doctors often rely on pulmonary metastasectomy, surgical removal of the pulmonary metastases, although current data for the practice specific to STS are limited. Lung metastasis produces symptoms similar to those of other serious lung or chest ailments. It is possible, however, for lung metastases to present no symptoms at all. Sometimes the cancerous growth is discovered by accident when the doctor takes a chest x-ray of the patient for other reasons

STS with lung metastases Diagnosis

The diagnosis of STS are mainly made by doing Imaging tests and by biopsy; however, the test is done after signs and symptoms occur. A regular x-ray of the area with the lump may be the first test ordered. A chest x-ray may be done after diagnosis to see if the sarcoma has spread to the lungs. A CT scan uses x-rays to make detailed cross-sectional images of the body. This test is also used to see if the sarcoma has spread to the lungs, liver, or other organs.

Continued in the report…..

STS with lung metastases Treatment

Metastases is a type of lung tumor that develops when cancer from another body site. When this occurs, the tumors in the lung are referred to as metastatic lung (pulmonary) tumors. Because it acts as a sieve for all of the blood that passes through the body, the lung is a very common site for metastatic tumors to lodge. Fortunately, patients with tumors that spread to the lung from other sites often still have a chance to be cured by surgical removal of these tumors, frequently in combination with chemotherapy. Early on, surgical therapy for sarcoma metastases was based on gaining adequate access and visualization to perform a complete resection, including removal of any occult or residual disease. Standard posterolateral thoracotomy provided excellent visualization and allowed the surgeon to examine the entire pleural surface. In surgery for pulmonary metastases complete resection of all lesions and preservation of lung parenchyma is of utmost importance. Pulmonary metastasectomy is performed heterogeneously not only concerning the surgical approach (open vs. VATS) but also to resection techniques (e.g., laser enucleation, electrocautery resection, stapling)

STS with lung metastases Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident cases of STS (Soft tissue sarcoma),Total incident cases of STS with lung metastases, Gender-specific incident cases of STS with lung metastases, and Subtype-specific incident cases of STS with lung metastases scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.

Key Findings

  • As per DelveInsight estimates, the incident cases of STS with lung metastases in the 7MM was 7,871 cases in 2017.
  • The estimates suggest a higher incidence of STS with lung metastases in the United States with 2,506 cases in 2017.
  • Females accounted for a larger percentage among the STS with lung metastases cases as compared to males. In 2017, a lower number of males were affected by this disease, i.e., 42% of the total incident cases of STS with lung metastases population in the United States, which is equivalent to 1,053 cases. In comparison to this, for females, the number of cases observed was 1,454 in 2017.
  • Among the total incidence of STS with lung metastases cases in the United States, there were 777 cases of Leiomyosarcoma, and 150 cases of liposarcoma, followed by synovial with 376 cases and other types with 1,203 cases.

.

STS with lung metastasesEpidemiology

The epidemiology segment also provides the STS with lung metastases epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

STS with lung metastases Drug Chapters

STS with lung metastases Emerging Drugs

Annamycin: Moleculin

Annamycin is a unique next-generation liposome formulated anthracycline (also referred to in the literature as "L-Annamycin") that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms that often defeat currently approved anthracyclines. Annamycin was discovered by Professor Waldemar Priebe at The University of Texas MD Anderson Cancer Center. Anthracyclines are a class of chemotherapy drugs considered to be among the most effectively available, and with a broader spectrum of anticancer activity than most other classes of chemotherapeutic agents. They have been recognized for their pleiotropic (producing or having multiple effects) mechanisms of action and for DNA being their primary target. In particular, anthracyclines interfere with an enzyme called "topoisomerase II," resulting in damage to the DNA of rapidly replicating tumor cells; such DNA damage leads to tumor cell death in a process called "apoptosis" (programmed cell death)

Products detail in the report…

STS with lung metastases Market Outlook

STS has many histologic subtypes, and the malignancy can be low or high grade. Treatment may include surgery, chemotherapy, radiation therapy, or a combination of these therapies. There have been many attempts to improve the treatment outcome of locally advanced or locally relapsed disease by combining local treatment (surgery, radiotherapy) with systemic therapy, such as neoadjuvant (preoperative) or adjuvant (postoperative) chemotherapy. However, only limited data are available, supporting the use of such perioperative treatments in sarcoma. Metastasectomy and/or chemotherapy are the most common treatments offered to patients with metastatic sarcoma. Pulmonary metastasectomy, either video-assisted or through a formal thoracotomy, has been shown to increase overall survival in select populations of both osseous and STS patients. While chemotherapy remains an essential tool for the treatment of patients with metastatic sarcoma, there is mixed evidence on its survival impact.

Surgical resection of pulmonary metastases and chemotherapy are treatment options that have been employed, but many patients are poor candidates for these treatments for multiple host or tumor-related reasons. In this group of patients, radiation might provide a less morbid treatment alternative. Furthermore, many older patients, as a result of various tumor or comorbidity-related issues, are deemed poor candidates for surgery or chemotherapy. External beam radiotherapy (EBRT) has been shown to decrease local recurrence when used in conjunction with surgery for primary localized STS. The use of stereotactic body radiation therapy (SBRT) for the treatment of metastatic carcinoma to the lung has been shown to be safe and effective. Previous reports on the use of SBRT for metastatic sarcoma to the lungs exist but are limited by small patient numbers and limited long-term follow-up.

Navarria et al., 2015b, conducted a study which stated that before SBRT, 36% of patients underwent surgical resection for other lung metastases, 18% of patients received chemotherapy, and seven (25%) patients received both treatments; SBRT was performed as the first treatment in 21% patients.

The pipeline of STS with lung metastases possesses potential drugs as monotherapies as well as combination therapies.

Key Findings

  • The market size of STS with lung metastases in the 7MM was USD 177.54 million in 2017.
  • Among the EU-5 countries, Germany has the highest market size of USD 23.71 million. The lowest market size was estimated in Italy, i.e., USD 11.40 million in 2017.
  • Around 65% of patients taking the first-line treatment experience relapse of the disease and go for second-line treatment. Since there are no approved or emerging therapies for relapsed/refractory treatment, the therapies which are used in the first-line are used again in second-line management.
  • The market size generated by surgery, off-label treatment, and SBRT (first line & second line treatment) in 2017 in the 7MM was estimated to be USD 110.52 million, USD 32.08 million, and USD 34.95 million, respectively.

The United States Market Outlook

This section provides the total STS with lung metastases market size and; market size by therapies in the United States.

EU-5 Market Outlook

The total STS with lung metastases market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total STS with lung metastases market size and market size by therapies in Japan are provided.

STS with lung metastases Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the STS with lung metastases market or expected to get launched in the market during the study period 2017-2030. The analysis covers the STS with lung metastases market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

STS with lung metastases Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for STS with lung metastases emerging therapies.

Reimbursement Scenario in STS with lung metastases

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the STS with lung metastases market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of STS with lung metastases, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the STS with lung metastases epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for STS with lung metastases is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the STS with lung metastases market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM STS with lung metastases market.

Report Highlights:

  • The robust pipeline with novel MOA and oral ROA, increasing incidence, effectiveness of drugs as both mono and combination therapy will positively drive the STS with lung metastases market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence STS with lung metastases R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for STS with lung metastases. The launch of emerging therapies will significantly impact the STS with lung metastases market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

STS with lung metastases Report Insights

  • Patient Population
  • Therapeutic Approaches
  • STS with lung metastases Pipeline Analysis
  • STS with lung metastases Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

STS with lung metastases Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • STS with lung metastases Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

STS with lung metastases Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Key Questions:

Market Insights:

  • What was the STS with lung metastases market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the STS with lung metastases total market size as well as market size by therapies across the 7MM during the forecast period (2020-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest STS with lung metastases market size during the forecast period (2020-2030)?
  • At what CAGR, the STS with lung metastases market is expected to grow at the 7MM level during the forecast period (2020-2030)?
  • What would be the STS with lung metastases market outlook across the 7MM during the forecast period (2020-2030)?
  • What would be the STS with lung metastases market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden, and unmet needs of STS with lung metastases?
  • What is the historical STS with lung metastases patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of STS with lung metastases at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to STS with lung metastases?
  • Out of the above-mentioned countries, which country would have the highest incident population of STS with lung metastases during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of STS with lung metastases along with the approved therapy?
  • What are the current treatment guidelines for the treatment of STS with lung metastases in the US and Europe?
  • What are the STS with lung metastases marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of STS with lung metastases?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of STS with lung metastases?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the STS with lung metastases therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for STS with lung metastases and their status?
  • What are the key designations that have been granted for the emerging therapies for STS with lung metastases?
  • What are the 7MM historical and forecasted market of STS with lung metastases?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the STS with lung metastases.
  • To understand the future market competition in the STS with lung metastases market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for STS with lung metastases in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the STS with lung metastases market.
  • To understand the future market competition in the STS with lung metastases market.

Table of Contents

1 Key Insights

2 Executive Summary of STS with lung metastases

3 STS with lung metastases Market Overview at a Glance

  • 3.1 Market Share (%) Distribution of STS with lung metastases in 2017
  • 3.2 Market Share (%) Distribution of STS with lung metastases in 2030

4 Disease Background and Overview: STS with lung metastases

  • 4.1 Introduction
  • 4.2 General symptoms of lung metastases
  • 4.3 Prognostic factors
    • 4.3.1 Histology
    • 4.3.2 Disease-free interval (DFI)
    • 4.3.3 Completeness of resection
    • 4.3.4 Response to chemotherapy
  • 4.4 Staging System
  • 4.5 Diagnosis of Soft-Tissue Sarcomas with Lung Metastases

5 Case Reports

  • 5.1 A multidisciplinary approach to giant soft tissue sarcoma of the chest wall: A case report
  • 5.2 Pneumothorax as an adverse event in patients with lung metastases of soft tissue sarcoma under Eribulin treatment
  • 5.3 Lung metastases of primary alveolar soft-part sarcoma occurring 20 years after initial treatment

6 Epidemiology and Patient Population

  • 6.1 Key Findings
  • 6.2 Epidemiology Methodology
  • 6.3 Total Incident Cases of Soft Tissue Sarcoma (STS) in the 7MM
  • 6.1 Total Incident Cases of STS with lung metastases in the 7MM

7 United States Epidemiology

  • 7.1 Assumptions and Rationale
  • 7.2 Total Incident cases of Soft tissue sarcoma (STS) in the United States
  • 7.3 Total incident cases of STS with lung metastases in the United States
  • 7.4 Gender-specific incident cases of STS with lung metastases in the United States
  • 7.5 Subtype-specific incident cases of STS with lung metastases in the United States

8 EU5 Epidemiology

  • 8.1 Assumptions and Rationale
  • 8.2 Germany Epidemiology
    • 8.2.1 Total incident cases of Soft tissue sarcoma (STS) in Germany
    • 8.2.2 Total incident cases of STS with lung metastases in Germany
    • 8.2.3 Gender-specific incident cases of STS with lung metastases in Germany
    • 8.2.4 Subtype-specific incident cases of STS with lung metastases in Germany
  • 8.3 France Epidemiology
    • 8.3.1 Total incident cases of Soft tissue sarcoma (STS) in France
    • 8.3.2 Total incident cases of STS with lung metastases in France
    • 8.3.3 Gender-specific incident cases of STS with lung metastases in France
    • 8.3.4 Subtype-specific incident cases of STS with lung metastases (%) in France
  • 8.4 Italy Epidemiology
    • 8.4.1 Total incident cases of Soft tissue sarcoma (STS) in Italy
    • 8.4.2 Total incident cases of STS with lung metastases in Italy
    • 8.4.3 Gender-specific incident cases of STS with lung metastases in Italy
    • 8.4.4 Subtype-specific incident cases of STS with lung metastases in Italy
  • 8.5 Spain Epidemiology
    • 8.5.1 Total incident cases of Soft tissue sarcoma (STS) in Spain
    • 8.5.2 Total incident cases of STS with lung metastases in Spain
    • 8.5.3 Gender-specific incident cases of STS with lung metastases in Spain
    • 8.5.4 Subtype-specific incident cases of STS with lung metastases (%) in Spain
  • 8.6 United Kingdom Epidemiology
    • 8.6.1 Total incident cases of Soft tissue sarcoma (STS) in the United Kingdom
    • 8.6.2 Total incident cases of STS with lung metastases in the UK
    • 8.6.3 Gender-specific incident cases of STS with lung metastases in the UK
    • 8.6.4 Subtype-specific incident cases of STS with lung metastases in the UK

9 Japan Epidemiology

  • 9.1 Assumptions and Rationale
    • 9.1.1 Total incident cases of Soft tissue sarcoma (STS) in Japan
    • 9.1.2 Total incident cases of STS with lung metastases in Japan
    • 9.1.3 Gender-specific incident cases of STS with lung metastases in Japan
    • 9.1.4 Subtype-specific incident cases of STS with lung metastases (%) in Japan

10 Current Treatment and Medical Practices

  • 10.1 Surgical Technique and Management
  • 10.2 Adjunctive therapies
  • 10.3 Treatment Algorithm

11 Unmet needs

12 Emerging Drugs

  • 12.1 Annamycin: Moleculin
    • 12.1.1 Product Description
    • 12.1.2 Other Developmental Activities
    • 12.1.3 Clinical Development
    • 12.1.4 Product Profile

13 Patient Journey

14 STS with lung metastases: 7MM Analysis

  • 14.1 Key Findings
  • 14.2 Market Methodology
  • 14.3 Market Size of STS with lung metastases in the 7MM
  • 14.4 Market Size of STS with lung metastases by Therapies in the 7MM

15 7MM Market Outlook

16 United States

  • 16.1 United States Market Size
    • 16.1.1 Total market size of STS with lung metastases in the United States
    • 16.1.2 Market Size of STS with lung metastases by Therapies in the US

17 EU-5 Countries

  • 17.1 Germany Market Size
    • 17.1.1 Total Market size of STS with lung metastases in Germany
    • 17.1.2 Market Size of STS with lung metastases by therapies in Germany
  • 17.2 France Market Size
    • 17.2.1 Total Market size of STS with lung metastases in France
    • 17.2.2 Market Size of STS with lung metastases by therapies in France
  • 17.3 Italy Market Size
    • 17.3.1 Total Market size of STS with lung metastases in Italy
    • 17.3.2 Market Size of STS with lung metastases by therapies in Italy
  • 17.4 Spain Market Size
    • 17.4.1 Total Market size of STS with lung metastases in Spain
    • 17.4.2 Market Size of STS with lung metastases by therapies in Spain
  • 17.5 United Kingdom Market Size
    • 17.5.1 Total Market size of STS with lung metastases in the United Kingdom
    • 17.5.2 Market Size of STS with lung metastases by therapies in the UK

18 Japan

  • 18.1 Japan Market Size
    • 18.1.1 Total Market size of STS with lung metastases in Japan
    • 18.1.2 Market Size of STS with lung metastases by therapies in Japan

19 Market Drivers

20 Market Barriers

21 SWOT Analysis

22 Recognized Establishments

23 Appendix

  • 23.1 Bibliography
  • 23.2 Report Methodology

24 DelveInsight Capabilities

25 Disclaimer

26 About DelveInsight

List of Tables

  • Table 1: Summary of STS with lung metastases, Market, Epidemiology and Key Events (2017-2030)
  • Table 2: Total Incident Cases of Soft Tissue Sarcoma (STS) in the 7MM (2017-2030)
  • Table 3: Total Incident Cases of STS with lung metastases in the 7MM (2017-2030)
  • Table 4: Total Incident cases of STS (Soft tissue sarcoma) in the United States (2017-2030)
  • Table 5: Total incident cases of STS with lung metastases in the United States (2017-2030)
  • Table 6: Gender-specific incident cases of STS with lung metastases in the US (2017-2030)
  • Table 7: Subtype-specific incident cases of STS with lung metastases in the US (2017-2030)
  • Table 8: Total incident cases of Soft tissue sarcoma (STS) in Germany (2017-2030)
  • Table 9: Total incident cases of STS with lung metastases in Germany (2017-2030)
  • Table 10: Gender-specific incident cases of STS with lung metastases in Germany (2017-2030)
  • Table 11: Subtype-specific incident cases of STS with lung metastases in Germany (2017-2030)
  • Table 12: Total incident cases of Soft tissue sarcoma (STS) in France (2017-2030)
  • Table 13: Total incident cases of STS with lung metastases in France (2017-2030)
  • Table 14: Gender-specific incident cases of STS with lung metastases in France (2017-2030)
  • Table 15: Subtype-specific incident cases of STS with lung metastases in France (2017-2030)
  • Table 16: Total incident cases of Soft tissue sarcoma (STS) in Italy (2017-2030)
  • Table 17: Total incident cases of STS with lung metastases in Italy (2017-2030)
  • Table 18: Gender-specific incident cases of STS with lung metastases in Italy (2017-2030)
  • Table 19: Subtype-specific incident cases of STS with lung metastases in Italy (2017-2030)
  • Table 20: Total incident cases of Soft tissue sarcoma (STS) in Spain (2017-2030)
  • Table 21: Total incident cases of STS with lung metastases in Spain (2017-2030)
  • Table 22: Gender-specific incident cases of STS with lung metastases in Spain (2017-2030)
  • Table 23: Subtype-specific incident cases of STS with lung metastases in Spain (2017-2030)
  • Table 24: Total incident cases of Soft tissue sarcoma (STS) in the UK (2017-2030)
  • Table 25: Total incident cases of STS with lung metastases in the UK (2017-2030)
  • Table 26: Gender-specific incident cases of STS with lung metastases in the UK (2017-2030)
  • Table 27: Subtype-specific incident cases of STS with lung metastases in the UK (2017-2030)
  • Table 28: Total incident cases of Soft tissue sarcoma (STS) in Japan (2017-2030)
  • Table 29: Total incident cases of STS with lung metastases in Japan (2017-2030)
  • Table 30: Gender-specific incident cases of STS with lung metastases in Japan (2017-2030)
  • Table 31: Subtype-specific incident cases of STS with lung metastases in Japan (2017-2030)
  • Table 32: Annamycin, Clinical Trial Description, 2020
  • Table 33: Market Size of STS with lung metastases in the 7MM in USD Million (2017-2030)
  • Table 34: Market Size of STS with lung metastases by therapies in the 7MM, in USD Million (2017 2030)
  • Table 35: The US Market Size of STS with lung metastases in USD Million (2017-2030)
  • Table 36: Market Size of STS with lung metastases by therapies in the US, in USD Million (2017-2030)
  • Table 37: Germany Market Size of STS with lung metastases in USD Million (2017-2030)
  • Table 38: Market Size of STS with lung metastases by therapies in Germany, in USD Million (2017-2030)
  • Table 39: France Market Size of STS with lung metastases in USD Million (2017-2030)
  • Table 40: Market Size of STS with lung metastases by therapies in France, in USD Million (2017-2030)
  • Table 41: Italy Market Size of STS with lung metastases in USD Million (2017-2030)
  • Table 42: Market Size of STS with lung metastases by therapies in Italy, in USD Million (2017-2030)
  • Table 43: Spain Market Size of STS with lung metastases in USD Million (2017-2030)
  • Table 44: Market Size of STS with lung metastases by therapies in Spain, in USD Million (2017-2030)
  • Table 45: The UK Market Size of STS with lung metastases in USD Million (2017-2030)
  • Table 46: Market Size of STS with lung metastases by therapies in the UK, in USD Million (2017-2030)
  • Table 47: Japan Market Size of STS with lung metastases in USD Million (2017-2030)
  • Table 48: Market Size of STS with lung metastases by therapies in Japan, in USD Million (2017-2030)

List of Figures

  • Figure 1: Diagnosis of Soft-Tissue Sarcoma with Lung Metastases
  • Figure 2: Imaging Tests for Soft-Tissue Sarcoma (STS)
  • Figure 3: Total Incident Cases of Soft Tissue Sarcoma (STS) in the 7MM (2017-2030)
  • Figure 4: Total Incident Cases of STS with lung metastases in the 7MM (2017-2030)
  • Figure 5: Total Incident cases of STS (Soft tissue sarcoma) in the United States (2017-2030)
  • Figure 6: Total incident cases of STS with lung metastases in the United States (2017-2030)
  • Figure 7: Gender-specific incident cases of STS with lung metastases in the US (2017-2030)
  • Figure 8: Subtype-specific incident cases of STS with lung metastases in the US (2017-2030)
  • Figure 9: Total incident cases of Soft tissue sarcoma (STS) in Germany (2017-2030)
  • Figure 10: Total incident cases of STS with lung metastases in Germany (2017-2030)
  • Figure 11: Gender-specific incident cases of STS with lung metastases in Germany (2017-2030)
  • Figure 12: Subtype-specific incident cases of STS with lung metastases in Germany (2017-2030)
  • Figure 13: Total incident cases of Soft tissue sarcoma (STS) in France (2017-2030)
  • Figure 14: Total incident cases of STS with lung metastases in France (2017-2030)
  • Figure 15: Gender-specific incident cases of STS with lung metastases in France (2017-2030)
  • Figure 16: Subtype-specific incident cases of STS with lung metastases in France (2017-2030)
  • Figure 17: Total incident cases of Soft tissue sarcoma (STS) in Italy (2017-2030)
  • Figure 18: Total incident cases of STS with lung metastases in Italy (2017-2030)
  • Figure 19: Gender-specific incident cases of STS with lung metastases in Italy (2017-2030)
  • Figure 20: Subtype-specific incident cases of STS with lung metastases in Italy (2017-2030)
  • Figure 21: Total incident cases of Soft tissue sarcoma (STS) in Spain (2017-2030)
  • Figure 22: Total incident cases of STS with lung metastases in Spain (2017-2030)
  • Figure 23: Gender-specific incident cases of STS with lung metastases in Spain (2017-2030)
  • Figure 24: Subtype-specific incident cases of STS with lung metastases in Spain (2017-2030)
  • Figure 25: Total incident cases of Soft tissue sarcoma (STS) in the UK (2017-2030)
  • Figure 26: Total incident cases of STS with lung metastases in the UK (2017-2030)
  • Figure 27: Gender-specific incident cases of STS with lung metastases in the UK (2017-2030)
  • Figure 28: Subtype-specific incident cases of STS with lung metastases in the UK (2017-2030)
  • Figure 29: Total incident cases of Soft tissue sarcoma (STS) in Japan (2017-2030)
  • Figure 30: Total incident cases of STS with lung metastases in Japan (2017-2030)
  • Figure 31: Gender-specific incident cases of STS with lung metastases in Japan (2017-2030)
  • Figure 32: Subtype-specific incident cases of STS with lung metastases in Japan (2017-2030)
  • Figure 33: Management of Soft Tissue Sarcoma
  • Figure 34: Management of localized, clinically resectable STS
  • Figure 35: Management of advanced/metastatic, clinically resectable STS
  • Figure 36: Management of advanced/metastatic, clinically unresectable STS
  • Figure 37: Unmet needs
  • Figure 38: Market Size of STS with lung metastases in the 7MM in USD Million (2017-2030)
  • Figure 39: Market Size of STS with lung metastases by therapies in the 7MM, in USD Million (2017-2030)
  • Figure 40: Market Size of STS with lung metastases in the US, USD Millions (2017-2030)
  • Figure 41: Market Size of STS with lung metastases by therapies in the US, in USD Million (2017-2030)
  • Figure 42: Market Size of STS with lung metastases in Germany, USD Millions (2017-2030)
  • Figure 43: Market Size of STS with lung metastases by Therapies in Germany, in USD Million (2017-2030)
  • Figure 44: Market Size of STS with lung metastases in France, USD Millions (2017-2030)
  • Figure 45: Market Size of STS with lung metastases by Therapies in France, in USD Million (2017-2030)
  • Figure 46: Market Size of STS with lung metastases in Italy, USD Millions (2017-2030)
  • Figure 47: Market Size of STS with lung metastases by Therapies in Italy, in USD Million (2017-2030)
  • Figure 48: Market Size of STS with lung metastases in Spain, USD Millions (2017-2030)
  • Figure 49: Market Size of STS with lung metastases by Therapies in Spain, in USD Million (2017-2030)
  • Figure 50: Market Size of STS with lung metastases in the UK, USD Millions (2017-2030)
  • Figure 51: Market Size of STS with lung metastases by Therapies in the UK, in USD Million (2017-2030)
  • Figure 52: Market Size of STS with lung metastases in Japan, USD Millions (2017-2030)
  • Figure 53: Market Size of STS with lung metastases by Therapies in Japan, in USD Million (2017-2030)
  • Figure 54: Market Drivers
  • Figure 55: Market Barriers
  • Figure 56: SWOT Analysis of STS with lung metastases